Crowdonomics
All companies
CAREMINDr logo

CAREMINDr

Operating

CAREMINDr Corporation

Healthcare · Technology · Los Gatos, CA · Founded 2017

Transforming the way patients receive care

Post-money valuation ⓘ
$35.5M
As of Sep 2022 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$1,089,702
Crowd $240K · Private $850K · 4 rounds since 2018
Latest share price
$1.48
Reg CF · Common Stock · Jun 2022 offering price

Financials

FY2020–FY2025 · from SEC filings · hover any figure for its source
$1K
−$1.4M
2020
$64K
−$808K
2021
$376K
−$747K
2022
$488K
−$701K
2023
$454K
−$549K
2024
$423K
−$735K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020 reviewed*
FY2021 unaudited
FY2022 unaudited
FY2023 unaudited
FY2024
FY2025
Income statement
Revenue
$1,365
$64,413
$376,103
$488,084
$453,535
$423,058
Cost of goods sold
$33,302
$4,432
$120,052
$127,500
$32,350
$128,000
Gross margin
-2340%
93%
68%
74%
93%
70%
Net income
-$1,372,552
-$807,561
-$747,371
-$701,148
-$549,051
-$734,768
Taxes paid
$919
$800
$800
$0
$34,981
$37,967
Balance sheet
Cash
$161,061
$61,857
$182,680
$123,718
$66,905
$31,089
Accounts receivable
$144
$18,004
$42,865
$13,060
$0
$8,488
Total assets
$161,205
$79,861
$225,545
$137,814
$135,831
$128,477
Short-term debt
$12,780
$187,132
$145,000
$450,924
$1,007,474
$1,619,130
Long-term debt
$3,055,500
$3,598,167
$3,625,500
$4,045,500
$0
$4,659,500
Total liabilities
$3,068,280
$3,785,299
$3,770,500
$4,496,424
$1,007,474
$6,278,630
Other
Headcount
—
10
10
10
—
10

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$35.1M
pre-money
Reg CF · Common · Jun 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Cap table

Share counts as of Apr 22, 2026
ClassOutstandingVotes / shareShare of totalLast price
Voting Common Stock12,000,0001100.0%$1.48Jun 2022

Principal holders% as the filing states it, Apr 22, 2026

  • SOZA 2002 REVOCABLE TRUST180,000 Non-Voting Common Stock40.5%of company
  • Daniel P. White200,000 Non-Voting Common Stock29.3%of company
  • Randall Coatney200,000 Non-Voting Common Stock29.3%of company
  • Everyone else (not named in filings)0.9%

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $239.7K / $1MInvestors 211Post-money $35.5M
Raised $550KInvestors 5
Raised $100KInvestors 1
Raised $200KInvestors 2

Team

7 people
Daniel P. WhiteFounder
Chief Financial Officer, Secretary, Treasurer & Director

Founder/Member of eight (8) successful startups during 25+ years in Silicon Valley B.A., Economics, Swarthmore College; M.B.A., Accounting and Finance, University of Chicago

Harry SozaFounder
President, CEO & Director

25+ years in senior management; 25+ years leading start-ups (four previous venture-backed companies) Founder/CEO - Resolution Health (2007: sold to WellPoint, $150M) - Preferred Solutions (1996: sold to PacifiCare, $32M) - two smaller tech companies (exits: non-public acquisition) MSEE-Stanford University; BSEE-University of Notre Dame

Randy CoatneyFounder
Chief Operating Officer & Director

25+ years of experience with technology and data companies in the health care industry. Member of Founding team in three successful start-up companies, venture financed B.S. - Iowa State University, Executive MBA - University of Colorado

Dr. Irina Yermilov
Chief Medical Officer

MD / MPHTM / MS / BS 10+ years experience in measuring cost and quality outcomes via claims & supplemental data, Consultant - UCLA Education & Research Institute Research Resident - RAND Corporation, General Surgery Residency - UCLA 40+ Professional Publications & Abstracts

Cherie Deeds
VP -Client Success, Western Region

Based in Los Angeles

Glen Markham
VP - Partnerships & Innovation

Over 20 years experience in healthcare technology. Worked with Senior Team members in a prior successful healthcare technology company.

Jennifer Gillooly Viola
VP - Client Success, Eastern Region

Based in central New Jersey

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 3 of 4 annual reports (FY2022–FY2025)

211 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form C-ARApr 22, 20260001738419-26-000002
    EDGAR
  • Form C-ARApr 18, 20240001665160-24-000381
    EDGAR
  • Form C-ARApr 17, 20230001665160-23-000627
    EDGAR
  • Form C-UOct 4, 20220001665160-22-002579
    EDGAR
  • Form C/AAug 12, 20220001665160-22-002202
    EDGAR
  • Form CMay 31, 20220001665160-22-001727
    EDGAR
  • Form DDec 2, 20190001738419-19-000002
    EDGAR
  • Form DMar 26, 20190001738419-19-000001
    EDGAR
Source: ManualCIK 0001738419DEShare price $1.48

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.